Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Sildenafil and cardioprotection.

Kukreja RC.

Curr Pharm Des. 2013;19(39):6842-7. Review.

PMID:
23590161
2.

PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.

Das A, Durrant D, Salloum FN, Xi L, Kukreja RC.

Pharmacol Ther. 2015 Mar;147:12-21. doi: 10.1016/j.pharmthera.2014.10.003. Epub 2014 Oct 31. Review.

3.

Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.

Kukreja RC, Ockaili R, Salloum F, Yin C, Hawkins J, Das A, Xi L.

J Mol Cell Cardiol. 2004 Feb;36(2):165-73. Review.

PMID:
14871543
4.

Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure.

Cvelich RG, Roberts SC, Brown JN.

Ann Pharmacother. 2011 Dec;45(12):1551-8. doi: 10.1345/aph.1Q421. Epub 2011 Nov 24. Review.

PMID:
22116990
5.

Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.

Ioakeimidis N, Kostis JB.

J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):53-64. doi: 10.1177/1074248413504034. Epub 2013 Nov 25. Review.

PMID:
24281316
6.

Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?

Doggrell S.

Int J Impot Res. 2007 May-Jun;19(3):281-95. Epub 2006 Dec 21. Review.

PMID:
17183346
7.

Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications.

Kukreja RC, Salloum F, Das A, Ockaili R, Yin C, Bremer YA, Fisher PW, Wittkamp M, Hawkins J, Chou E, Kukreja AK, Wang X, Marwaha VR, Xi L.

Vascul Pharmacol. 2005 Apr-May;42(5-6):219-32. Epub 2005 Mar 29. Review.

PMID:
15922255
8.

Cardioprotection with sildenafil: implications for clinical practice.

Raja SG.

Curr Med Chem. 2006;13(26):3155-64. Review.

PMID:
17168704
9.

[Update of PDE5 inhibitors as treatment of ED].

Lu YN, Chen B.

Zhonghua Nan Ke Xue. 2005 Jul;11(7):552-5. Review. Chinese.

PMID:
16078679
10.

Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.

Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O.

Adv Ther. 2009 Sep;26(9):813-25. doi: 10.1007/s12325-009-0064-z. Epub 2009 Sep 19. Review.

PMID:
19768639
11.

Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.

Chaumais MC, Perrin S, Sitbon O, Simonneau G, Humbert M, Montani D.

Expert Opin Drug Metab Toxicol. 2013 Sep;9(9):1193-205. doi: 10.1517/17425255.2013.804063. Epub 2013 Jun 12. Review.

PMID:
23944387
12.

PDE5 inhibitor treatment options for urologic and non-urologic indications: 2012 update.

Gur S, Kadowitz PJ, Serefoglu EC, Hellstrom WJ.

Curr Pharm Des. 2012;18(34):5590-606. Review.

PMID:
22747425
13.

[Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors].

Herlemann A, Gratzke C, Andersson KE, Sievert KD.

Urologe A. 2013 Feb;52(2):204-11. doi: 10.1007/s00120-012-3084-2. Review. German.

PMID:
23417046
14.

[Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension].

Kiliçkesmez K, Küçükoğlu MS.

Anadolu Kardiyol Derg. 2010 Sep;10 Suppl 2:16-8. doi: 10.5152/akd.2010.125. Review. Turkish.

15.

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M.

Eur Urol. 2012 May;61(5):994-1003. doi: 10.1016/j.eururo.2012.02.033. Epub 2012 Feb 25. Review.

PMID:
22405510
16.

[Phosphodiesterase inhibitors: effectiveness and new applications].

van Driel MF.

Ned Tijdschr Geneeskd. 2006 Jul 22;150(29):1613-6. Review. Dutch.

PMID:
16901064
17.

[Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension].

Sakuma M, Shirato K.

Nihon Rinsho. 2008 Nov;66(11):2157-61. Review. Japanese.

PMID:
19051736
18.

Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.

Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH.

Cardiol Rev. 2007 Mar-Apr;15(2):76-86. Review.

PMID:
17303994
19.

Phosphodiesterase 5 inhibitors for erectile dysfunction.

Setter SM, Iltz JL, Fincham JE, Campbell RK, Baker DE.

Ann Pharmacother. 2005 Jul-Aug;39(7-8):1286-95. Epub 2005 Jun 7. Review.

PMID:
15941818
20.

PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials.

Zhuang XD, Long M, Li F, Hu X, Liao XX, Du ZM.

Int J Cardiol. 2014 Apr 1;172(3):581-7. doi: 10.1016/j.ijcard.2014.01.102. Epub 2014 Jan 24. Review.

PMID:
24534379

Supplemental Content

Support Center